Noriyuki Namba

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Monoclonal Antibody

Ejection Fraction

Patient Reported

Top Venues

Endocrine journal

The Journal of clinical endocrinology and metabolism

Calcified tissue international

This page only lists publications with an associated author ORCID identifier.

Publications

Toshimi Michigami, Hee Gyung Kang, Noriyuki Namba, Nobuaki Ito, Takuo Kubota, Ayumi Shintani, Daijiro Kabata, Masanori Kanematsu, Yayoi Nishida, Seiji Fukumoto, Keiichi Ozono
Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study. JBMR plus 8 (8) (2024)
Toshimi Michigami, Hee Gyung Kang, Noriyuki Namba, Nobuaki Ito, Takuo Kubota, Ayumi Shintani, Daijiro Kabata, Masanori Kanematsu, Yayoi Nishida, Seiji Fukumoto, Keiichi Ozono
Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study. JBMR plus 8 (8) (2024)
Yuki Kawashima-Sonoyama, Keisuke Wada, Kei Yamamoto, Masanobu Fujimoto, Noriyuki Namba, Takeshi Taketani
Clinical characteristics of and growth hormone treatment effects on short stature with type 1 insulin-like growth factor receptor (IGF1R) gene alteration. Endocrine journal (2024)
Yuki Kawashima-Sonoyama, Keisuke Wada, Kei Yamamoto, Masanobu Fujimoto, Noriyuki Namba, Takeshi Taketani
Clinical characteristics of and growth hormone treatment effects on short stature with type 1 insulin-like growth factor receptor (IGF1R) gene alteration. Endocrine journal 71 (7) (2024)
Yuki Kawashima-Sonoyama, Keisuke Wada, Kei Yamamoto, Masanobu Fujimoto, Noriyuki Namba, Takeshi Taketani
Clinical characteristics of and growth hormone treatment effects on short stature with type 1 insulin-like growth factor receptor (IGF1R) gene alteration. Endocrine journal 71 (7) (2024)
Noriyuki Namba, Takuo Kubota, Koji Muroya, Hiroyuki Tanaka, Masanori Kanematsu, Masahiro Kojima, Shunichiro Orihara, Hironori Kanda, Yoshiki Seino, Keiichi Ozono
Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial. Journal of the Endocrine Society 6 (5) (2022)
Leanne M Ward, Francis H Glorieux, Michael P Whyte, Craig F Munns, Anthony A Portale, Wolfgang Högler, Jill H Simmons, Gary S Gottesman, Raja Padidela, Noriyuki Namba, Hae Il Cheong, Ola Nilsson, Meng Mao, Angel Chen, Alison Skrinar, Mary Scott Roberts, Erik Allen Imel
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia. The Journal of clinical endocrinology and metabolism 107 (8) (2022)
Raja Padidela, Michael P Whyte, Francis H Glorieux, Craig Frank Munns, Leanne M Ward, Ola Nilsson, Anthony A Portale, Jill H Simmons, Noriyuki Namba, Hae Il Cheong, Pisit Pitukcheewanont, Etienne Sochett, Wolfgang Högler, Koji Muroya, Hiroyuki Tanaka, Gary S Gottesman, Andrew Biggin, Farzana Perwad, Angela Williams, Annabel Nixon, Wei Sun, Angel Chen, Alison Skrinar, Erik Allen Imel
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcified tissue international 108 (5) (2021)